Efficacy of porcine versus bovine surfactants for preterm newborns with respiratory distress syndrome: Systematic review and meta-analysis

Pediatrics

Volumn 128, Issue 6, 2011, Pages

  Singh, Neetu ^a   Hawley, Kristy L ^b   Viswanathan, Kristin ^c  

^a DARTMOUTH HITCHCOCK MEDICAL CENTER   (United States)

^b GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^c Board of Health Sciences Policy   (United States)

Author keywords

Beractant; Calfactant; Poractant alfa; Pulmonary surfactant

Indexed keywords

BERACTANT; CALFACTANT; OXYGEN; PORACTANT;

DRUG EFFICACY; DRUG MEGADOSE; GESTATIONAL AGE; HUMAN; INFANT; INFANT MORTALITY; INTUBATION; LOW DRUG DOSE; META ANALYSIS; NEONATAL RESPIRATORY DISTRESS SYNDROME; NEWBORN; OXYGEN THERAPY; PREMATURITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REPEATED DRUG DOSE; REVIEW; SYSTEMATIC REVIEW; TREATMENT OUTCOME;

ANIMALS; CATTLE; HUMANS; INFANT, NEWBORN; PULMONARY SURFACTANTS; RESPIRATORY DISTRESS SYNDROME, NEWBORN; SWINE;

EID: 83155176162     PISSN: 00314005     EISSN: 10984275     Source Type: Journal    
DOI: 10.1542/peds.2011-1395     Document Type: Review

References (24)

1. Soll RF. Prophylactic synthetic surfactant for preventing morbidity and mortality in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD001079
2. Soll R, Blanco F. Natural surfactant extract versus synthetic surfactant for neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2001;(2):CD000144
3. Soll R. Synthetic surfactant for respiratory distress syndrome in preterm infants. Cochrane Database Syst Rev. 2000;(2):CD001149
4. Soll R, Ozek E. Multiple versus single doses of exogenous surfactant for the prevention or treatment of neonatal respiratory distress syndrome. Cochrane Database Syst Rev. 2009;(1):CD000141
5. Ramanathan R. Animal-derived surfactants: where are we? The evidence from randomized, controlled clinical trials. J Perinatol. 2009;29(suppl 2):S38-S43
6. Engle WA; American Academy of Pediatrics, Committee on Fetus and Newborn. Surfactant-replacement therapy for respiratory distress in the preterm and term neonate. Pediatrics. 2008;121(2):419-432
7. Higgins JPT, Green S, eds. Cochrane Handbook for Systematic Reviews of Interventions 4.2.6. Chichester, United Kingdom: Wiley; 2006
8. International Committee for Classification of Retinopathy of Prematurity. An international classification of retinopathy of prematurity. Pediatrics. 1984;74(1):127-133
9. Papile LA, Burstein J, Burstein R, Koffler H. Incidence and evolution of subependymal and intraventricular hemorrhage: a study of infants with birth weights less than 1,500 gm. J Pediatr. 1978;92(4):529-534
10. Baroutis G. Comparison of treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Eur J Pediatr. 2004;163(2):127-128
11. Fujii A, Patel S, Allen R, Doros G, Guo C, Testa S. Poractant alfa and beractant treatment of very premature infants with respiratory distress syndrome. J Perinatol. 2010;30(10):665-670
12. Fujii A, Allen R, Doros G, O'Brien S. Patent ductus arteriosus hemodynamics in very premature infants treated with poractant alfa or beractant for respiratory distress syndrome. J Perinatol. 2010;30(10):671-676
13. Gharehbaghi MM, Sakha SH, Ghojazadeh M, Firoozi F. Complications among premature neonates treated with beractant and poractant alfa. Indian J Pediatr. 2010;77(7):751-754
14. Malloy CA, Nicoski P, Muraskas JK. A randomized trial comparing beractant and poractant treatment in neonatal respiratory distress syndrome. Acta Paediatr. 2005;94(6):779-784
15. Ramanathan R, Rasmussen MR, Gerstmann DR, Finer N, Sekar K; North American Study Group. A randomized, multicenter masked comparison trial of poractant alfa (Curosurf) versus beractant (Survanta) in the treatment of respiratory distress syndrome in preterm infants. Am J Perinatol. 2004;21(3):109-119
16. Speer CP, Gefeller O, Groneck P, et al. Randomised clinical trial of two treatment regimens of natural surfactant preparations in neonatal respiratory distress syndrome. Arch Dis Child Fetal Neonatal Ed. 1995;72(1):F8-F13
17. Fox GF, Sothinathan U. The choice of surfactant for treatment of respiratory distress syndrome in preterm infants: a review of the evidence. Infant. 2005;1(1):8-12
18. Halliday HL. Recent clinical trials of surfactant treatment for neonates. Biol Neonate. 2006;89(4):323-329
19. Moya F, Maturana A. Animal-derived surfactants versus past and current synthetic surfactants: current status. Clin Perinatol. 2007;34(1):145-177
20. Ramanathan R. Choosing a right surfactant for respiratory distress syndrome treatment. Neonatology. 2009;95(1):1-5
21. Halliday HL. Surfactants: past, present and future. J Perinatol. 2008;28(suppl 1):S47-S56
22. Halahakoon W. A Study of Cerebral Function Following Surfactant Treatment for Respiratory Distress Syndrome [MD thesis]. Belfast, Northern Ireland: Queen's University; 1999
23. Marsh W, Smeeding J, York JM, Ramanathan R, Sekar K. A cost minimization comparison of two surfactants-beractant and poractant alfa-based upon prospectively designed, comparative clinical trial data. J Pediatr Pharmacol Ther. 2004;9:117-125
24. Gerdes JS, Seiberlich W, Sivieri EM, et al. An open-label comparison of calfactant and poractant alfa administration traits and impact on neonatal intensive care unit resources. J Pediatr Pharmacol Ther. 2006; 11(2):92-100